meanwhile, demand for defibrillators, which give the heart a small electric shock when an irregular heartbeat or rhythm is detected, is expected to increase, analysts said. the move by johnson johnson has been widely expected and the firm will pay 76 for each guidant share, 6% more than wednesday's closing price. j j agrees 25bn guidant deal pharmaceutical giant johnson johnson has agreed to buy medical technology firm guidant for 25.4bn 13bn . a number of johnson johnson's products are facing patent expirations, while the company is also battling fierce competition from generic products. analysts said that the deal is aimed at offsetting johnson johnson's reliance on a slowing drug business.